Avalon GloboCare Announces Notice of Publication for Key U.S. Patent Filed Jointly With the Massachusetts Institute of Technology (MIT)
Avalon GloboCare Announces Notice of Publication for Key U.S. Patent Filed Jointly With the Massachusetts Institute of Technology (MIT)
Patent for Multiple Novel QTY-Code Modified Cytokine and Chemokine Protein Receptor Molecules
多種新型 QTY-code 修飾的細胞因子和趨化因子蛋白受體分子的專利
FREEHOLD, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Publication for U.S. Patent No. 11,555,060, titled "QTY Fc Fusion Water Soluble Receptor Proteins." The publication may be accessed through the USPTO's publicly available Searchable Databases via the Internet at .
新澤西州弗裏霍爾德，2023年9月5日（GLOBE NEWSWIRE）— Avalon GloboCare Corp.（“Avalon” 或 “公司”）（納斯達克股票代碼：ALBT）創新精密診斷的開發商和臨床實驗室服務提供商，今天宣佈，美國專利商標局（USPTO）已發佈美國專利第11,555,060號的發佈通知，標題爲 “QTY Fc融合水溶性受體蛋白”。該出版物可通過美國專利商標局的公開可搜索數據庫通過互聯網訪問，網址爲。
The patent covers the composition of matter and methodology for multiple novel QTY-Code modified cytokine and chemokine protein receptor molecules. The patent was jointly filed with Dr. Shuguang Zhang of the Massachusetts Institute of Technology (MIT).
該專利涵蓋多種新型QTY-code修飾的細胞因子和趨化因子蛋白受體分子的物質組成和方法。該專利是與麻省理工學院（MIT）的張曙光博士共同申請的。
The "QTY Code" is a breakthrough technology that can turn difficult to work with water-insoluble transmembrane receptor proteins into water-soluble proteins, greatly enhancing the solubility of designer peptides and proteins, therefore potentially expanding the repertoire of selected therapeutic targets against cancers and other diseases.
“QTY Code” 是一項突破性技術，它可以將難以處理的水不溶性跨膜受體蛋白轉化爲水溶性蛋白，從而極大地增強了設計肽和蛋白質的溶解度，從而有可能擴大針對癌症和其他疾病的特定治療靶點的範圍。
"We are pleased to announce this notice of publication from the USPTO for our QTY code protein design platform, which was developed together with Professor Shuguang Zhang's laboratory at MIT," stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. "Our patented technology can turn water-insoluble proteins that normally reside within cellular membranes—and that can be difficult to work within the laboratory—into water-soluble proteins that can be potentially used in many clinical applications. The resulting soluble, antibody-like cytokine/chemokine decoy receptors derived using the QTY protein design, have many potential applications, including, among others, mitigation of the "cytokine storm" associated with COVID-19 and cellular immunotherapy delivery, as well as broadening the range of therapeutic targets addressable by CAR T-cell therapies."
Avalon GloboCare總裁兼首席執行官金大衛博士表示：“我們很高興地宣佈，美國專利商標局發佈了我們的QTY代碼蛋白設計平台的通知，該平台是與麻省理工學院張曙光教授的實驗室共同開發的。”“我們的專利技術可以將通常存在於細胞膜中的水不溶性蛋白質轉化爲可能用於許多臨床應用的水溶性蛋白質，這些蛋白質可能在實驗室中使用。由此產生的可溶性、類似抗體的細胞因子/趨化因子誘餌受體使用 QTY 蛋白設計具有許多潛在的應用，包括緩解與 COVID-19 和細胞免疫療法給藥相關的 “細胞因子風暴”，以及擴大 CAR T 細胞療法可解決的治療靶標範圍。”
About Avalon GloboCare Corp.
關於 Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: ALBT) is a commercial stage company dedicated to developing and delivering innovative, transformative, precision diagnostics and clinical laboratory services. Avalon is establishing a leading role in the innovation of diagnostic testing, utilizing proprietary technology to deliver precise, genetics-driven results. The Company also provides laboratory services, offering a broad portfolio of diagnostic tests including drug testing, toxicology, and a broad array of test services, from general bloodwork to anatomic pathology, and urine toxicology. For more information about Avalon GloboCare, please visit .
Avalon GloboCare Corp.（納斯達克股票代碼：ALBT）是一家商業舞臺公司，致力於開發和提供創新、變革性、精確的診斷和臨床實驗室服務。Avalon 利用專有技術提供精確的、以遺傳學爲導向的結果，在診斷測試的創新中樹立了主導地位。該公司還提供實驗室服務，提供廣泛的診斷測試組合，包括藥物測試、毒理學和廣泛的測試服務，從普通血液檢查到解剖病理學以及尿液毒理學。有關 Avalon GloboCare 的更多信息，請訪問。
For the latest updates on Avalon GloboCare's developments, please follow our twitter at @avalongc_avco.
有關 Avalon GloboCare 發展的最新動態，請關注我們的推特，網址爲 @avalongc_avco。
Forward-Looking Statements
前瞻性陳述
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, including statements regarding LSM. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.
本新聞稿中包含的某些陳述可能構成 “前瞻性陳述”。前瞻性陳述根據某些假設提供對未來事件的當前預期，包括任何與任何歷史或當前事實無直接關係的陳述，包括有關LSM的陳述。由於我們在美國證券交易委員會網站上向美國證券交易委員會提交的文件中披露的各種重要因素，實際業績可能與此類前瞻性陳述所顯示的結果存在重大差異（除了這些因素外，由於更一般的因素，包括（但不限於）一般行業和市場狀況以及增長率、經濟狀況以及政府和公共政策變化，未來的實際業績、業績和業績可能存在重大差異。本新聞稿中包含的前瞻性陳述代表了公司截至本新聞稿發佈之日的觀點，這些觀點可能會發生變化。但是，儘管公司可能會選擇在未來的某個時候更新這些前瞻性陳述，但公司明確表示不承擔任何這樣做的義務。截至新聞稿發佈之日之後的任何日期，不應依賴這些前瞻性陳述來代表公司的觀點。
Contact Information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com
聯繫信息：
Avalon GloboCare 公司
4400 9 號公路，3100 套房
新澤西州弗裏霍爾德 07728
PR@Avalon-GloboCare.com
Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
albt@crescendo-ir.com
投資者關係：
克雷森多通訊有限責任公司
電話：(212) 671-1020 分機 304
albt@crescendo-ir.com
譯文內容由第三人軟體翻譯。